Non-Hodgkin Lymphoma, Multiple Myeloma

Non-Hodgkin Lymphoma, Multiple Myeloma

About GDA-201

GDA-201 is an innate natural killer (NK) cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. When combined with targeted antibodies, GDA-201 has shown enhanced antibody-dependent cellular toxicity, or ADCC.

Clinical Trial Information

GDA-201 is being evaluated in a Phase 1 clinical study in patients with refractory non-Hodgkin lymphoma and multiple myeloma.

In an oral presentation at the American Society of Hematology (ASH) 62nd Annual Meeting in December 2020, it was shown that GDA-201 was well tolerated and no dose-limiting toxicities were observed in the Phase 1 clinical study. GDA-201 demonstrated significant clinical activity in patients with non-Hodgkin lymphoma, with 13 complete responses and one partial response observed in 19 patients, for a response rate of 74 percent. Details of the presentation can be found in the press release.

For more information about the study, please visit www.clinicaltrials.gov.

Send us a message